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Background: Alzheimer’s disease is a very common, progressive and still incurable disease. Future possibilities for
its cure lie in the promotion of research that will increase our knowledge of the disorder’s causes and lead to the
discovery of effective remedies. Such research will necessarily involve individuals suffering from Alzheimer’s disease.
This raises the controversial issue of whether patients with Alzheimer’s disease are competent to give their consent
for research participation.
Discussion: We discuss the case of subjects with Alzheimer’s disease who may have impaired decision-making
capacity and who could be involved in research protocols, taking into consideration aspects of the Italian normative
framework, which requires a court-appointed legal representative for patients who are not able to give consent and
does not recognise the legal value of advance directives. We show that this normative framework risks preventing
individuals with Alzheimer’s disease from taking part in research and that a new policy that favours research while
promoting respect for patients’ well-being and rights needs to be implemented.
Summary: We believe that concerns about the difficulty of obtaining fully valid consent of patients with Alzheimer’s
disease should not prevent them from participating in clinical trials and benefiting from scientific progress. Therefore,
we argue that the requirement for patients to have a legal representative may not be the best solution in all countries
and clinical situations, and suggest promoting the role of patients’ family members in the decision-making process. In
addition, we outline the possible role of advance directives and ethics committees.
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Alzheimer’s disease (AD) is a very common, progressive
and still incurable disease. It is estimated that AD along
with other dementias with similar clinical profiles affect
an estimated 35.6 million people—around 0.5% of the
global population [1]. Although some studies show a
substantial decrease in dementia prevalence [2] and a
substantial increase in cognitive performance and activities
of daily living in elderly people [3] in some high-income
countries, ‘even with a small decrease in incidence and
prevalence, population ageing will still double the num-
bers with dementia worldwide in the next generation’ [4].* Correspondence: cporteri@fatebenefratelli.it
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Organization [5].
In Italy, there are approximately 700,000 people with
AD and 80,000 new cases per year [6]. Though the cap-
acity to diagnose this disease even at a prodromal stage
has continued to improve [7], effective opportunities for
treatment and prevention are still lacking. Current drugs
(i.e. cholinesterase inhibitors and memantine) can pro-
vide symptomatic relief for a number of patients but
cannot delay disease progression. Unfortunately, these
drugs, together with cognitive training and rehabilita-
tion, for which there is still no indication of any signifi-
cant benefit [8], are the only real options available today.
This disease has devastating effects on the lives of pa-
tients and their caregivers and has important social and
economic implications. The future possibilities of a cure
lie in research that can increase our knowledge of theentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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fective remedies, both in terms of biological changes and
clinical improvements. Such research will necessarily
involve individuals suffering from AD. This raises the
controversial issue of whether patients with AD are
competent to give consent for research participation.
In this paper, we discuss the situation of individuals
with AD who may have impaired decision-making cap-
acity and who might be involved in research protocols,
taking into consideration aspects of the Italian norma-
tive framework, which risks preventing this population
from participating in research. We suggest a possible
way to aid research while promoting the well-being and
rights of patients involved in clinical trials.
We chose to consider AD because it is the most com-
mon form of dementia, accounting for 50 to 80% of all
dementia cases [1], and is currently the object of the
largest research investments and the most extensive
literature. Nevertheless, our discourse can be applied to
other dementias too.
Discussion
Consent for research by incompetent patients
Informed consent is a fundamental ethical and legal
requirement of biomedical research to ensure that par-
ticipants are not objects of exploitation but, on the
contrary, are considered autonomous subjects entitled
to be informed and make decisions for themselves. In
cases where the interested person is judged unable to
give consent, international guidelines (WMA Helsinki
Declaration [9]; CIOMS International Ethical Guidelines
for Biomedical Research Involving Human Subjects [10])
and European regulations (Directive 2001/20/EC [11];
Additional protocol to the convention on human rights
and biomedicine, concerning biomedical research [12];
Regulation (EU) No 536/2014 [13]) require consent from
the person’s legal representative. Directive 2001/20/EC
has been transposed into national laws by member states
and, since its enforcement, has been the common frame-
work for clinical trials in the European Union. In Italy,
the directive has been enforced by the Legislative Decree
no. 211, 24 June 2003 [14].
The new Regulation (EU) no 536/2014, which came
into force on 16th June 2014 (but will not be applicable
until 6 months after a new EU portal and database have
become fully functional, and not before 28 May 2016),
repeals that directive and establishes a new set of har-
monised rules that member states should apply in clin-
ical trials. Both the directive and the regulation allow the
inclusion of incapacitated adults (who have not given or
not refused informed consent before the onset of their
incapacity) only if ‘the informed consent of their legally
designated representative has been obtained’ (Regulation
EU 536/2014, art. 31.a).Based on the European normative framework, national
legislation specifies which persons can act as a patient’s
representative: ‘Regarding the rules concerning the de-
termination of the legally designated representatives of
incapacitated persons and minors, those rules diverge in
member states. It should therefore be left to member
states to determine the legally designated representatives
of incapacitated persons and minors’ (Regulation EU
536/2014, Whereas 27).
This implies that approaches to the appointment of a
patient’s legal representative may differ across member
states depending on the legal, cultural and political back-
ground of each European country, giving rise to proce-
dures of differing complexity that may affect biomedical
research. Information on European legislations has been
compiled [15-17] and the issue has been discussed in a
significant number of commentaries [18-22].
The main distinction can be drawn between countries
where the legal representative must be appointed by the
court, as in Austria, Germany and Italy, and countries
that, although with some differences in the implementa-
tion of the provision, have adopted a more pragmatic
procedure involving a cascade of measures to arrive at
consent on behalf of the subject, ranging from the
authorised legal representative to family members and
close persons. These countries include member states
that specify a hierarchy of family members to be con-
tacted, such as Belgium, Hungary, The Netherlands and
Norway, as well as countries with more general provi-
sions, such as Denmark, Finland, France, Ireland, the
United Kingdom, Spain and Sweden, where there must
be a close relationship between the subject and their
representative. In France, authorisation is required from
a judge if an ethics committee rules that the research
imposes serious risks to the participants. In countries
like the United Kingdom, Denmark and Ireland, profes-
sional representatives may give consent on behalf of
the patient provided they are not connected to the
clinical trials.
In Italy, a legal representative has to be appointed by
the court in a case-by-case manner to comply with the
rules of the Italian Civil Code [23]. This procedure ap-
plies both for biomedical research and for health-related
treatments. Before the approval of Law 6/2004 [24] that
instituted guardianship [amministratore di sostegno] and
modified Title XII of the Italian Civil Code, the only
possible legal representative for an incompetent adult
was the tutore. A tutore could be appointed through a
slow, costly and permanent procedure either for acts of
extraordinary administration (i.e. disqualification) or for
acts of both extraordinary and ordinary administration
(i.e. proscription). Both measures have a serious impact
on the person concerned, whose interests are conse-
quently handled by the appointed representative in
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have largely fallen into disuse. Law 6/2004 permits a
quicker and less costly way to appoint a legal representa-
tive for vulnerable individuals and facilitates an import-
ant change in the way that vulnerable people are viewed
[25]. In fact, the traditional institutions of disqualification
and proscription completely deprived a person of her
legal rights, while guardianship focuses on the person’s
care and assistance needs. Moreover, the person in ques-
tion may indicate in advance her representative, and she
maintains the capacity to act in all aspects that are not
explicitly included in the responsibilities of the amminis-
tratore di sostegno.
For the above reasons, in health-related issues, the
amministratore di sostegno is a better option than the
tutore for circumstances in which a person clearly needs
a legal representative.
Nevertheless, there are some important considerations
with respect to AD patients’ participation in biomedical
research, namely: i) the case of appointing a legal repre-
sentative just for research participation; ii) the case of
uncertain capacity; and iii) the case of collaborative
research.
The case of appointing a legal representative just for
research participation
Most people with AD who attend memory clinics and
are potential research subjects do not have a legal repre-
sentative at the time they are asked to take part in re-
search. Previous experiences show that the requirement
of a legal representative as a condition for the enrolment
of patients in a clinical trial is a major obstacle to re-
search and may prevent the implementation of the trial.
This was the case in the AdCare study, a non-profit, ran-
domised, placebo-controlled, double-blind, multicentre
trial coordinated by the Italian National Institute of
Health, which aimed to evaluate the long-term safety
and efficacy profiles of atypical and conventional anti-
psychotic drugs. The study planned to include 19 clinical
centres with the enrolment of 1000 outpatients suffering
from AD. According to Italian law, in cases where the
research team evaluated a patient as unable to give in-
formed consent, a legal representative designated by the
court was asked to provide consent on behalf of the pa-
tient. This requirement led to serious difficulties in the
enrolment of subjects; consequently, the study was pre-
maturely suspended. From February 2009 to April 2010,
only 83 patients gave informed consent to participate in
the trial. Fifty-six patients (68%) were included with con-
sent given by a legal representative, while 27 patients
(32%) were considered able to provide their own in-
formed consent after an assessment of their competence
[26]. A sub-study on legal agency was performed at one
of the centres involved in the AdCare study and involved172 patients. The results showed that only three partici-
pants were acquainted with Law 6/2004. More than half
of the patient/relative couples chose not to initiate the
procedure for the appointment of a legal representative,
while 46% applied for the appointment. The mean time
interval between the presentation of the law by the re-
search team and the application to the court was
2 months. The mean time interval between the applica-
tion to the court and the completion of the appointment
was 4 months (double the maximum time prescribed by
the law). Seventy percent of applications resulted in
the appointment of a legal representative. The study
found that the subjects who decided to apply for a
legal representative were usually younger, had been
suffering from dementia for longer and had fewer than
two children [18].
The above evidence shows that the request for a legal
representative for patients’ participation in clinical trials
is not really practicable within the current Italian legal
framework for at least two reasons: first, the time
needed to appoint the legal representative, which inevit-
ably slows down the research schedule, and second, the
attitudes and sensitivity of the patients’ family members.
The latter reason should be seriously considered. As for
the AdCare study, clinical practice shows that very few
patients with dementia have a legal representative.
Moreover, it is uncommon to initiate the legal procedure
for the appointment of a representative unless there are
compelling reasons to do so (e.g. for the management of
assets). This may be because of a lack of information
about the figure of the amministratore di sostegno and
his or her role. However, it may also be that many family
members have reservations about starting a legal pro-
cedure that somehow limits the patient’s power, even if
the goal is to protect the patient. In this sense, the sug-
gestion that a legal representative be appointed just for
the sake of participation in a research study, as well as
being infeasible, seems hardly justified. Similar consider-
ations can be extended to people who are competent at
the time of enrolment in the research protocol but lose
their capacity during the trial. Under the current Italian
regulations, a legal representative should be appointed
for those patients; however, there are likely to be difficul-
ties with feasibility and family members’ willingness to
start the legal procedure in this situation too.
The case of uncertain capacity
The appointment of a legal representative does not an-
swer the most interesting and difficult issue regarding
the capacity of patients with AD; that is, the uncertain
capacity of the subjects.
A diagnosis of dementia does not in itself mean that
the subject is unable to understand and express valid
informed consent. This view is often reflected in the
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often too easily assumed that people with dementia are
incapable of making choices and decisions. Empirical
studies that have assessed patients both in real-life con-
ditions (i.e. during enrolment in clinical trials) and in
hypothetical conditions using a range of instruments
and methods for assessing research-related decision-
making capacity [27] show that, although patients with
AD perform worse than other patients and healthy sub-
ject control groups, they may be able to understand, ap-
preciate, reason and express a valid choice when asked
to take part in a research project [28-34]. Nevertheless,
some patients have variable and borderline capacities
and have been evaluated by researchers as ‘marginally
competent’, ‘sufficiently competent’ [35] or ‘borderline
competent’ [36]. Moreover, the judgement of compe-
tence/incompetence for patients with dementia is an es-
pecially difficult task and physicians may frequently
disagree in their competency judgements, particularly in
cases of mild to moderate dementia [37-39]. In addition,
thresholds based on normative values or expert judge-
ment can differ in terms of how many people are evalu-
ated as incapable on at least one ability related to
decision making [31], and agreement between standar-
dised assessment methods and physicians’ judgement of
competency may be poor for people with dementia [40].
However, research indicates that willingness to partici-
pate in research is similar for subjects with decisional
impairment due to AD and healthy comparison subjects,
showing that impaired subjects as a group are able to
distinguish between research protocols with varying
risk/benefit profiles [41]. Moreover, AD patients’ capacity
performance may vary depending on the complexity and
risk of trials, and even people evaluated as unable to give
consent for research protocols may preserve the capacity
to appoint a research proxy [32]. This suggests that
competency is not a unitary concept or construct [42]
and that while AD patients may lose the capacity to per-
form a specific act, they may retain the capacity for
other affairs.
As the Nuffield Council on Bioethics [43] states in ref-
erence to individuals with dementia, ‘In many cases, it
will be very clear whether a person with dementia does
or does not have the capacity to make a particular deci-
sion. However, there will be times when the person’s
ability to make a particular decision will be difficult to
determine’. This ‘grey zone’ cannot be considered under
the law, which assumes that a person either has or does
not have the capacity to make a particular decision at a
particular point in time; however, this is a very common
situation, particularly in individuals in the earliest stages
of dementia. Underestimating the uncertainty of sub-
jects’ capacity may have significant consequences for pa-
tients who, depending on a physician’s judgement ofcompetence, would be free to express their wishes and
choose for themselves or, alternatively, would be sub-
jected to resolutions taken for them by other people,
which might result in their wishes not being fulfilled.
For subjects in the grey zone, in which capacity is un-
certain and its judgement difficult, consent on the sub-
ject’s behalf may be the best solution to protect health
professionals. However, we believe that this is not a good
solution from an ethical perspective because it hu-
miliates subjects and limits their potential to express
themselves.
The case of collaborative research
Opportunities to increase our prevention, diagnosis,
treatment and care of people affected by AD can only be
found in coordinated actions that unite the efforts of all
those involved in this type of research. In Europe, the
European Commission firmly invited countries ‘to pool
their resources and better coordinate their research efforts
in the field of neurodegenerative diseases, and Alzheimer’s
in particular, by programming their research investments
jointly for the first time, instead of each separately’ [44].
The fact that member states share the same regula-
tions on clinical trials, which require (among other
conditions) a legal representative in cases of incompe-
tent adults, but have different legal procedures for the
appointment of representatives, might delay research in
some countries, such as Italy, where the procedure is
burdensome. More importantly, this may be an obstacle
to research on dementia and neurodegenerative disor-
ders and may therefore inhibit the ability to make im-
portant discoveries.
Suggestions for a possible solution
Informed consent should be regarded as a means to pro-
tect and promote the interests and rights of subjects
within the medical sphere. A subject’s lack of capacity to
give informed consent cannot solely be a sufficient rea-
son to exclude that subject from participation in re-
search. Such exclusion, far from protecting the subject,
would prevent patients with AD from receiving possible
benefits from research.
We have argued that the requirement for a legal repre-
sentative may not be the best solution with respect to
the research participation of patients with AD, even
when it is quite clear that patients are unable to decide
for themselves and, particularly, when their capacity is
uncertain. Nevertheless, alternative measures that pro-
tect frail patients and that promote their interests and
rights should be implemented.
The role of family members
Family members should play a major role in situations
where it is impractical to appoint a legal representative
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for subjects who are in the grey zone. This would also
help to remove obstacles to collaborative research
among European countries that do not share national
legal requirements.
The possibility that a family member, even one not
appointed by a judge as a legal representative, may make
decisions on behalf of the patient needs careful consider-
ation. From an ethical perspective, the most important
requirement for a patient’s representative is that he or
she has previously spent time and shared experiences
with the patient and currently has a close relationship
with them. This helps ensure that the representative is
able to give a voice to the patient’s wishes and that the
patient’s well-being is his or her primary concern. In this
sense, the involvement of family members of patients
with AD who have a poor understanding and decision-
making capacity is valuable in ensuring that patients’
wishes and previous values and beliefs are respected
[45]. For subjects with uncertain or variable capacity,
‘joint decision-making with trusted family members’
might help to bridge the gap between the point at which
a person with dementia is fully able to make their own
decisions and the time when formal proxy decision mak-
ing becomes necessary on a regular basis [43]. This type
of decision making may also bridge the gap between
those periods when AD symptoms manifest more
strongly and periods when they are weaker. The majority
of clinical trials involving patients with AD require the
active presence of a caregiver as an inclusion criterion.
In most cases, the patients’ caregivers are members of
the family. This means that family members are fully in-
formed of the research protocol and are asked to moni-
tor the patient during the trial and to collaborate with
the research team in collecting information on the pa-
tient’s condition. We suggest that family members could
be involved further and that researchers should trust
that the opinions of family members regarding a pa-
tient’s participation in a clinical trial reflect what is most
beneficial for an individual patient in a particular situ-
ation. This is also consistent with the law that estab-
lished the amministratore di sostegno [46]. The law
allows a hierarchy of family members to be appointed as
legal proxy, including the beneficiary’s spouse, his or her
partner, father or mother, son or daughter, brother or
sister, or any other person who is close to the patient.
Therefore, the law recognises that family members are
the best legal representatives. Within the current legal
framework, however, family members cannot sign the in-
formed consent form on behalf of the patient unless they
are the court-appointed legal representatives. Neverthe-
less, the information given to them and their opinions
can be recorded. They can also sign a form confirming
that they have received the information and haveunderstood and appreciated it. This should be regarded,
particularly by ethics committees, as proof of a prudent
enrolment of patients in a clinical trial.
Our proposal to involve family members in the
decision-making process is supported by empirical sur-
vey results. Family surrogate consent for AD research is
supported both by the general public [47,48] and by
people closer to the disease, such as caregivers and pri-
mary decision-makers for persons with dementia [49],
and people at risk for AD [50]. A further argument in
support of family members’ involvement in dementia re-
search relates to the above-mentioned evidence that
people suffering from AD can retain the capacity to ap-
point a proxy decision-maker even when they lose the
capacity to give consent to research participation [32].
However, one study investigating consent practices of
researchers in aging reported the soliciting of consent
from family members to include people deemed incap-
able of consent in research protocols, even in jurisdic-
tions where such authority is uncertain at law [51].
The involvement of family members can potentially
extend the patient’s autonomy when it is compromised
and does not exclude the patient from the decision-
making process. In addition, patients would receive
information according to their capacity for comprehen-
sion. This means that studies should provide straightfor-
ward, simple information and should avoid technical
jargon and details that are not essential to a broad un-
derstanding of the research project. Furthermore, a
patient’s refusal to participate in research would be
respected. A risk nevertheless exists that proxies may
persuade and influence patients, and may override pa-
tients’ desires in favour of what they consider is in the
patient’s best interest [52]. Because of the specific Italian
normative legal framework, we suggest that family mem-
bers should also play a crucial role when the patient has
previously expressed an advance directive.
The case of advance directives
Advance directives are an effective way to extend the
autonomy of individuals who were previously able to de-
cide for themselves but are currently incapable of deci-
sion making because of their pathological conditions.
Advance directives are clearly limited because they can-
not encompass all possible biomedical situations. Never-
theless, they may cover every aspect of research and
treatment related to the subject’s health. These directives
may include participation in biomedical research al-
though this is uncommon [53,54] and efforts are needed
to raise awareness about this matter [55]. Even now,
advance directives in Italy have no legal value, although
a discussion about them has begun in Parliament.
Nonetheless, clear indications of the value and legit-
imacy of advance directives can be found in the Italian
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indications also feature in the Convention on Human
Rights and Biomedicine [57] ratified into the Italian legis-
lation and in the opinion of the Italian National Bioethics
Committee on advance treatment statements [58], which
suggests that the principle of advance directives has been
accepted. We agree with the Italian Society of Neurology
bioethics group [59] that advance directives are particu-
larly valuable and effective for patients who have previ-
ously been deemed competent if they include the
appointment of a trusted person who can contribute to
the decision-making process in the context of current
medical/scientific possibilities, on the basis of the indi-
cations given by the patient and his or her values and
past life. The appointed trusted person should be in-
volved in decisions about research participation even
when explicit choices on the matter are not included in
the patient’s directives, as her appointment shows
unambiguously the patient’s trust and will to be repre-
sented. In the context of advance directives, the pa-
tient’s family member, whether explicitly appointed as
trusted person or not appointed, would play a crucial
role in respecting those directives.
The role of the research ethics committees
The involvement of family members in the decision-
making process is not a substitute for other require-
ments for the implementation of biomedical research in-
volving patients with poor or uncertain capacity. These
requirements set out the conditions for offers of re-
search participation to such patients and should be ful-
filled. They specify the following: that the proposed
research is essential to validate data; such research re-
lates directly to the subject’s clinical condition; clinical
trials have been designed to minimise pain, discomfort,
fear and any other foreseeable risk; and the expected
benefit will outweigh the risks or the trial will produce
no risk at all [11]. The requirements for good communi-
cation with the patient and for the clinical assess-
ment of capacity should also be fulfilled. All of these
requirements should be considered first by the re-
search sponsor during the planning of the research
protocol and then by the ethics committee, whose role is
to ‘protect the dignity, rights, safety and well-being of
research participants’ [12].
With regard to the family members of patients who
are invited to take part in a research study, ethics com-
mittees should acknowledge their role as persons who
extend the autonomy of patients and who are strongly
interested in the patient’s health and well-being. In
this sense, ethics committees should accept family
members’ opinions about the patient’s participation
in a clinical trial as valid decisions regarding the patient’s
enrolment.To ensure that every effort to respect patients’ auton-
omy and wishes has been made [60], ethics committees
should require research protocols to describe the planned
informed consent process, as follows: the methods and in-
struments used to assess patients’ competence, the pos-
sible presence of an independent evaluator of competence
and an independent auditor of the informed consent
process, the method used to identify the patients’ repre-
sentatives, and the value given to advance directives
expressed by patients when they were fully competent.
We recognise that providing an independent evaluator of
competence and an auditor of informed consent might be
difficult, although not impossible, at least in qualified cen-
tres. Ethics committees should nevertheless be informed
about the planned consent process, and they would evalu-
ate on a case-by-case basis if this provides sufficient
protection for the prospective participants. Last, mem-
bers of research ethics committees might also personally
supervise the enrolment of patients in situations where
they judge this is important, even though supervision re-
quires human resources that ethics committees rarely
have.
It is widely assumed that not every kind of research
deserves the same level of subject protection. This
should be judged according to the benefit/risk ratio of
the research protocols; that is, the level of protection
should be progressively higher in relation to an increase
in risks and a decrease in expected benefits. On the
basis of ethical recommendations [61] and the ethics
committees’ evaluation, some of the above sugges-
tions could be deemed essential while others could be
deemed excessive and discounted. However, in our opin-
ion, the requirement to involve patients’ family members
in the biomedical research consent process should be
preserved.
Summary
In accordance with the National Bioethics Advisory
Commission report [61], we stress the importance of re-
search aimed to increase knowledge of the decision-
making capacity of individuals with mental disorders,
the best ways of assessing that capacity, and the methods
that can improve the process of informed consent. At
the same time, we consider that concerns about the dif-
ficulty of obtaining fully valid consent of patients with
AD should not prevent them from potentially taking
part in clinical trials and benefiting from scientific pro-
gress. We argue that the requirement for patients to
have a legal representative may not be the best solution
in all countries and clinical situations and suggest that
the role of patients’ family members in the decision-
making process should be promoted. In addition, we
highlight the possible role of advance directives and
ethics committees.
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